NEEDHAM, Mass. (February 10, 2026) — Trialt, a global clinical research organization (CRO) specializing in biostatistics, statistical programming, data management, and medical writing, today announced ...
CANTON, Mich. (January 29, 2026) – MMS, a global, data-focused clinical research organization (CRO), today announced it has been named a finalist in the 2026 Association for Clinical Data Management ...
We’re delighted to announce that Lisa Steinmetz has been promoted to clinical operations manager for the Division of Infectious Diseases. Since 2023, Steinmetz has served as ambulatory services ...
Clinical management guidelines are typically focused on individual conditions and lack a robust evidence base for patients with MLTC. MLTC management is largely delivered in primary care, where health ...
Data has always played a central role in patient care and medical research. But today, data is driving healthcare transformation at an unprecedented pace. From the rise of EHRs to the emergence of AI, ...
Belenos Biosciences Inc., a private, clinical-stage biotechnology company today announced that its China partner Keymed Biosciences has reported topline results from a Phase 1b study (n=46) of BEL512 ...
Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...
Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
The Department of Veterans Affairs has increasingly been using immersive technologies, like augmented reality and virtual reality headsets, to supplement healthcare offerings for retired ...
Healthcare providers receive data from many disparate sources: hospitals, doctors’ offices, labs and lab machines, medical devices, pharmacies, and more. Investment in the correct infrastructure to ...
Management reaffirmed that the ALPHA3 futility analysis and MRD conversion data will be shared in the first half of 2026. The company expects 2025 cash burn of approximately $150 million and full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results